艾德生物(300685.SZ):擬轉讓SDC2產品權益及子公司艾之維股權
格隆匯6月5日丨艾德生物(300685.SZ)公佈,2022年6月2日,公司及其子公司廈門廈維健康科技有限公司(“廈門廈維”)與杭州艾維克生物科技有限公司(“杭州艾維克”)簽署《技術轉讓及許可協議》,公司擬出售SDC2產品所有權及相關的知識產權以及生產、商業化SDC2產品相應的經濟權益(以下統稱“標的產品”),轉讓價款為1億元;廈門艾德生物醫藥科技股份有限公司與上海艾之理企業管理合夥企業(有限合夥)、上海艾之德企業管理合夥企業(有限合夥)及杭州艾維克生物科技有限公司簽署《股權轉讓協議》,公司擬出售持有的控股子公司上海艾之維健康科技有限公司的80%股權,對應公司認繳出資額1600萬元,實繳出資額0元,此次股權轉讓價格為0元,此次股權轉讓完成後,公司將不再持有上海艾之維健康科技有限公司的股權。
公司成立十餘年,聚焦腫瘤精準醫療領域,專注於科技惠民的技術創新,致力於為腫瘤患者提供合規、高品質的診斷產品和服務,公司經營穩健,常年保持可持續的盈利性成長態勢,在業內獨樹一幟。目前具備精準醫療條件的各大癌種,公司具備了從樣本保護、核酸提取、分子診斷試劑、儀器,到自動報吿及數據管理系統的全流程整體解決方案。伴隨分子診斷技術的進步和醫學研究的進展,新的市場應用場景不斷湧現,公司產品線亦逐漸從腫瘤藥物伴隨診斷拓展到遺傳風險評估、疾病早測、療效監測等。人類SDC2基因甲基化檢測試劑盒(熒光PCR法)於2021年1月獲批,是公司首個獲批的腫瘤早測產品,考慮到1)腫瘤早測產品的商業化模式有別於腫瘤藥物伴隨診斷以醫療機構為主的銷售渠道,與公司現有銷售團隊難以形成協同效應;2)腫瘤早測市場需要長期大量的資源投入,能否在未來為公司帶來持續收益存在一定不確定性,因此本次出售上述資產是公司進行腫瘤早測產品新商業推廣模式的一次嘗試,公司將繼續發揮多年積澱的研發優勢,佈局簡便、快捷、低成本的其他癌種早測產品的開發及註冊報批。
此次交易完成後,預計此次交易增加淨利潤約8500萬元,如果此次交易在2022年12月31日前完成交割,則該損益影響金額將計入公司2022年度財務報表,具體金額以審計報吿為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.